RTOG Symposium COX-2 Inhibitors and Cancer Therapeutics
COX-2 Inhibitors and Cancer Therapeutics: Potential Roles for Inhibitors of COX-2 in Combination With Cytotoxic Therapy : Reports From a Symposium Held in Conjunction With the Radiation Therapy Oncology Group June 2001 Meeting
Development of COX Inhibitors in Cancer Prevention and Therapy
COX-2 Inhibitors as Radiosensitizing Agents for Cancer Therapy
Rofecoxib (Vioxx), a Specific Cyclooxygenase-2 Inhibitor, Is Chemopreventive in a Mouse Model of Colon Cancer
Cyclooxygenase-2 (COX-2) Enzyme Inhibitors and Radiotherapy : Preclinical Basis
COX-2 Inhibitor as a Radiation Enhancer : New Strategies for The Treatment of Lung Cancer
Cyclooxygenase-2 (COX-2) and Epidermal Growth Factor Receptor (EGFR) Expression in Human Pituitary Macroadenomas
Initial Experience Combining Cyclooxygenase-2 Inhibition with Chemoradiation for Locally Advanced Pancreatic Cancer
Combination of a COX-2 Inhibitor With Radiotherapy or Radiochemotherapy in the Treatment of Thoracic Cancer
Effect of the Combination of Docetaxel, Zoledronic Acid, and a COX-2 Inhibitor on the Growth of Human Breast Cancer Cell Lines
Cyclooxygenase-2 (COX-2) Expression in Human Meningioma as a Function of Tumor Grade
Combination of Radiation and Celebrex (Celecoxib) Reduce Mammary and Lung Tumor Growth
COX-2 Inhibitors as Radiation Sensitizers for Upper GI Tract Cancers: Esophagus, Stomach, and Pancreas
Celecoxib Reduces Skin Damage After Radiation : Selective Reduction of Chemokine and Receptor mRNA Expression in Irradiated Skin but Not in Irradiated Mammary Tumor
Why Cyclooxygenase-2 Inhibition Plus Chemotherapy?